ScholarIQanswers from OpenAlex

Clinical Efficacy and Safety of Nivolumab: Results of a M ulticenter, Op e n-label, Single-a r m, Japanese Phase II study in Mal i gnant Pleural Meso t helioma (MERIT)

PaperCitations, authors & open-access status

Clinical Efficacy and Safety of Nivolumab: Results of a M ulticenter, Op e n-label, Single-a r m, Japanese Phase II study in Mal i gnant Pleural Meso t helioma (MERIT) is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Clinical Efficacy and Safety of Nivolumab: Results of a M ulticenter, Op e n-label, Single-a r m, Japanese Phase II study in Mal i gnant Pleural Meso t helioma (MERIT) have?

ScholarIQcitation count

When was Clinical Efficacy and Safety of Nivolumab: Results of a M ulticenter, Op e n-label, Single-a r m, Japanese Phase II study in Mal i gnant Pleural Meso t helioma (MERIT) published?

ScholarIQyear

Open the OpenAlex record →

What is the open-access status of Clinical Efficacy and Safety of Nivolumab: Results of a M ulticenter, Op e n-label, Single-a r m, Japanese Phase II study in Mal i gnant Pleural Meso t helioma (MERIT)?

ScholarIQoa status

Open the OpenAlex record →

What is the DOI of Clinical Efficacy and Safety of Nivolumab: Results of a M ulticenter, Op e n-label, Single-a r m, Japanese Phase II study in Mal i gnant Pleural Meso t helioma (MERIT)?

ScholarIQdoi

The DOI for Clinical Efficacy and Safety of Nivolumab: Results of a M ulticenter, Op e n-label, Single-a r m, Japanese Phase II study in Mal i gnant Pleural Meso t helioma (MERIT) is on the source record.

Open the DOI →

What is the PMID of Clinical Efficacy and Safety of Nivolumab: Results of a M ulticenter, Op e n-label, Single-a r m, Japanese Phase II study in Mal i gnant Pleural Meso t helioma (MERIT)?

ScholarIQpmid

The PMID for Clinical Efficacy and Safety of Nivolumab: Results of a M ulticenter, Op e n-label, Single-a r m, Japanese Phase II study in Mal i gnant Pleural Meso t helioma (MERIT) is on the source record.

Open the PMID →

What is the OpenAlex record for Clinical Efficacy and Safety of Nivolumab: Results of a M ulticenter, Op e n-label, Single-a r m, Japanese Phase II study in Mal i gnant Pleural Meso t helioma (MERIT)?

ScholarIQopenalex

The OpenAlex for Clinical Efficacy and Safety of Nivolumab: Results of a M ulticenter, Op e n-label, Single-a r m, Japanese Phase II study in Mal i gnant Pleural Meso t helioma (MERIT) is on the source record.

Open the OpenAlex →

Clinical Efficacy and Safety of Nivolumab: Results of a <u>M</u> ulticenter, Op <u>e</u> n-label, Single-a <u>r</u> m, Japanese Phase II study in Mal <u>i</u> gnant Pleural Meso <u>t</u> helioma (MERIT)

How many citations does Clinical Efficacy and Safety of Nivolumab: Results of a <u>M</u> ulticenter, Op <u>e</u> n-label, Single-a <u>r</u> m, Japanese Phase II study in Mal <u>i</u> gnant Pleural Meso <u>t</u> helioma (MERIT) have?

When was Clinical Efficacy and Safety of Nivolumab: Results of a <u>M</u> ulticenter, Op <u>e</u> n-label, Single-a <u>r</u> m, Japanese Phase II study in Mal <u>i</u> gnant Pleural Meso <u>t</u> helioma (MERIT) published?

What is the open-access status of Clinical Efficacy and Safety of Nivolumab: Results of a <u>M</u> ulticenter, Op <u>e</u> n-label, Single-a <u>r</u> m, Japanese Phase II study in Mal <u>i</u> gnant Pleural Meso <u>t</u> helioma (MERIT)?

What is the DOI of Clinical Efficacy and Safety of Nivolumab: Results of a <u>M</u> ulticenter, Op <u>e</u> n-label, Single-a <u>r</u> m, Japanese Phase II study in Mal <u>i</u> gnant Pleural Meso <u>t</u> helioma (MERIT)?

What is the PMID of Clinical Efficacy and Safety of Nivolumab: Results of a <u>M</u> ulticenter, Op <u>e</u> n-label, Single-a <u>r</u> m, Japanese Phase II study in Mal <u>i</u> gnant Pleural Meso <u>t</u> helioma (MERIT)?

What is the OpenAlex record for Clinical Efficacy and Safety of Nivolumab: Results of a <u>M</u> ulticenter, Op <u>e</u> n-label, Single-a <u>r</u> m, Japanese Phase II study in Mal <u>i</u> gnant Pleural Meso <u>t</u> helioma (MERIT)?

Related on ScholarIQ